Review
doi: 10.1177/0961203309360539.
Epub 2010 Feb 9.
Ocular side effects of anti-rheumatic medications: what a rheumatologist should know
Affiliations
- PMID: 20144965
- PMCID: PMC2926651
- DOI: 10.1177/0961203309360539
Item in Clipboard
Review
Ocular side effects of anti-rheumatic medications: what a rheumatologist should know
Lupus.
2010 May.
Abstract
Nearly every drug may cause changes to ocular tissues through a variety of mechanisms. Medication overdoses, drug-drug interactions but also chronic administration of medications at the recommended doses may lead to ocular toxicity. The ocular side effects, screening for eye toxicity and treatment guidelines for anti-inflammatory and immunosuppressive drugs commonly used by rheumatologists are reviewed herein.
Similar articles
-
Medical treatment of adolescents with rheumatic disease.Adolesc Med. 1998 Feb;9(1):163-70, vii. Adolesc Med. 1998. PMID: 10961259 Review.
-
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) Syndrome and the Rheumatologist.Curr Rheumatol Rep. 2017 Jan;19(1):3. doi: 10.1007/s11926-017-0626-z. Curr Rheumatol Rep. 2017. PMID: 28138822 Review.
-
Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.Curr Opin Rheumatol. 1989 Jun;1(1):74-9. doi: 10.1097/00002281-198901010-00015. Curr Opin Rheumatol. 1989. PMID: 2577111 Review. No abstract available.
-
Disease-modifying antirheumatic drugs: gold, penicillamine, antimalarials, and sulfasalazine.Curr Opin Rheumatol. 1990 Jun;2(3):489-96. doi: 10.1097/00002281-199002030-00013. Curr Opin Rheumatol. 1990. PMID: 1975503 Review. No abstract available.
-
Guidelines for use of antirheumatic drugs.J Rheumatol Suppl. 1994 Sep;41:79-81. J Rheumatol Suppl. 1994. PMID: 7799391
Cited by
-
Combination of doxycycline, streptomycin and hydroxychloroquine for short-course treatment of brucellosis: a single-blind randomized clinical trial.Infection. 2022 Oct;50(5):1267-1271. doi: 10.1007/s15010-022-01806-x. Epub 2022 Mar 30. Infection. 2022. PMID: 35353333 Free PMC article. Clinical Trial.
-
Development and External Validation of a Nomogram for Predicting the Effect of RTX on the Treatment of Membranous Nephropathy.J Inflamm Res. 2023 Oct 6;16:4399-4411. doi: 10.2147/JIR.S428218. eCollection 2023. J Inflamm Res. 2023. PMID: 37822530 Free PMC article.
-
Ocular Manifestations in Colombian Patients with Systemic Rheumatologic Diseases.Clin Ophthalmol. 2021 Jun 28;15:2787-2802. doi: 10.2147/OPTH.S306621. eCollection 2021. Clin Ophthalmol. 2021. PMID: 34234401 Free PMC article.
-
Understanding Ocular Findings and Manifestations of Systemic Lupus Erythematosus: Update Review of the Literature.Int J Mol Sci. 2022 Oct 14;23(20):12264. doi: 10.3390/ijms232012264. Int J Mol Sci. 2022. PMID: 36293119 Free PMC article. Review.
-
Antiarthritic Activity of Achyranthes Aspera on Formaldehyde - Induced Arthritis in Rats.Open Access Maced J Med Sci. 2019 Aug 30;7(17):2709-2714. doi: 10.3889/oamjms.2019.559. eCollection 2019 Sep 15. Open Access Maced J Med Sci. 2019. PMID: 31844425 Free PMC article.
References
-
- Rousseau GG, Baxter JD, Tomkins GM. Glucocorticoid receptors: relations between steroid binding and biological effects. J Mol Biol. 1972;67:99–115. - PubMed
-
- Chrousos GP. The hypothalamic–pituitary–adrenal axis and immune-mediated inflammation. N Engl J Med. 1995;332:1351–1362. - PubMed
-
- Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol. 2000;11:478–483. - PubMed
-
- Waterbury L, Kunysz EA, Beuerman R. Effects of steroidal and non-steroidal anti-inflammatory agents on corneal wound healing. J Ocul Pharmacol. 1987;3:43–54. - PubMed
-
- Haimovici R, Gragoudas ES, Duker JS, et al. Central serous chorioretinopathy associated with inhaled or intranasal corticosteroids. Ophthalmology. 1997;104:1653–1660. - PubMed
